Kunming Longjin Pharmaceutical Co.,Ltd.

The company built its factory in 1991, and after nearly 30 years of forging ahead, it has now developed into a modern biotechnology pharmaceutical enterprise integrating research, production, supply and marketing. The company has always been engaged in R&D, production (including pharmaceutical CMO business) and sales of Chinese and Western pharmaceuticals. The company's representative products include Longjin's “injectable dengzhanhuacin, injectable fibrosis, injectable bivalirudine, injectable somatostatin, and Jinleshu” seven-flavor sugar pulse capsules. The dosage forms cover freeze-dried powder injections and oral doses. Corporate honors: Famous trademarks and invention patents in Yunnan Province, 2017 Best Process Innovation Award, 2017 Kunming Famous Brand, “Outstanding Chinese Medicine Brand Enterprise”, “China's Top 100 Traditional Chinese Medicine Enterprises”, “China's Top 100 Pharmaceutical Industry Series List”, “Yunnan Top 100 Non-public Enterprises”, “2023 Yunnan Top 100 High-tech Enterprises”, “Kunming Health Enterprise”, “Typical Case of Digital Transformation of Listed Companies in 2023”, etc.